logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9724341 B1

PDFFull Text
Date of Patent:
Aug. 08, 2017

Filed:

Jul. 11, 2014

Nicotine salt with meta-salicylic acid

Applicant:

Alexza Pharmaceuticals, Inc., Mountain View, CA (US);

Inventors:

Daniel J. Myers, Mountain View, CA (US);

James Cassella, Essex, CT (US);

Assignee:

ALEXZA PHARMACEUTICALS, INC., Mountain View, CA (US);

Attorney:

Swanson & Bratschun, L.L.C.

Primary Examiner:

Theodore R West

Int. Cl.
CPC ...
A61K 31/465 (2006.01); A61M 15/06 (2006.01); A61K 9/00 (2006.01); A61K 31/60 (2006.01); A61M 5/00 (2006.01); A61M 11/04 (2006.01); A61M 35/00 (2006.01); A61M 37/00 (2006.01); C07D 401/04 (2006.01); C07C 63/08 (2006.01); H05B 1/02 (2006.01); A24B 15/16 (2006.01); A24F 47/00 (2006.01); C07C 65/10 (2006.01); A61K 9/70 (2006.01); A61M 11/00 (2006.01); A61M 15/00 (2006.01); A61M 16/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/465 (2013.01); A24B 15/167 (2016.11); A24F 47/002 (2013.01); A61K 9/0004 (2013.01); A61K 9/007 (2013.01); A61K 31/60 (2013.01); A61M 5/00 (2013.01); A61M 11/041 (2013.01); A61M 15/0065 (2013.01); A61M 15/0081 (2014.02); A61M 15/0083 (2014.02); A61M 15/06 (2013.01); A61M 35/00 (2013.01); A61M 37/00 (2013.01); C07C 63/08 (2013.01); C07C 65/10 (2013.01); C07D 401/04 (2013.01); H05B 1/025 (2013.01); A61K 9/7007 (2013.01); A61M 11/001 (2014.02); A61M 11/042 (2014.02); A61M 11/047 (2014.02); A61M 15/002 (2014.02); A61M 15/0066 (2014.02); A61M 2016/0015 (2013.01); A61M 2205/276 (2013.01); A61M 2205/3368 (2013.01); A61M 2205/3553 (2013.01); A61M 2205/3569 (2013.01); A61M 2205/3576 (2013.01); A61M 2205/3584 (2013.01); A61M 2205/3592 (2013.01); A61M 2205/364 (2013.01); A61M 2205/368 (2013.01); A61M 2205/3653 (2013.01); A61M 2205/50 (2013.01); A61M 2205/52 (2013.01); A61M 2205/8206 (2013.01); A61M 2209/06 (2013.01); A61M 2230/06 (2013.01); A61M 2230/205 (2013.01); A61M 2230/30 (2013.01); A61M 2230/42 (2013.01); C07C 2101/16 (2013.01);
Abstract

The present disclosure relates generally to the field of nicotine delivery. The disclosure teaches a nicotine meta-salicylate. More specifically, the disclosure teaches a condensation nicotine aerosol where nicotine meta-salicylate is vaporized. This disclosure relates to aerosol nicotine delivery devices. The delivery devices can be activated by actuation mechanisms to vaporize thin films comprising a nicotine meta-salicylate. More particularly, this disclosure relates to thin films of nicotine salt with meta salicylic acid for the treatment of nicotine craving and for effecting smoking cessation.

Find Patent Forward Citations

Loading…